Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

Analysis of Rare Disruptive Germline Mutations in 2,135 Enriched BRCA-Negative Breast Cancers Excludes Additional High-Impact Susceptibility Genes

Homoharringtonine Demonstrates A Cytotoxic Effect Against Triple-Negative Breast Cancer Cell Lines and Acts Synergistically With Paclitaxel

Dr Gatti-Mays Speaks on Advances in Triple Negative Breast Cancer

Dr. Lajos Pusztai Speaks on the KEYNOTE-522 Trial

Dr George Speaks on Advances in Triple Negative Breast Cancer

Annual Mammograms for Older Breast Cancer Survivors

Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer

header-info

Sep, 19, 2022

William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the importance of understanding tumor biology before choosing a treatment option.